BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy BCTX?
Source: Newsfilter
Bria-OTS+ Platform Presentation: BriaCell Therapeutics will present its next generation Bria-OTS+ platform, showcasing its strong anti-cancer activity and immune system engagement at the SITC Annual Meeting on November 7, 2025.
Clinical Trials and Funding: The lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have completed GMP manufacturing and are set for clinical trials, with Bria-PROS+ receiving a $2 million NCI SBIR award to support its evaluation.
Innovative Immunotherapy: Bria-OTS+ is an advanced immunotherapy platform designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules, building on the positive results of its predecessor, Bria-OTS™.
Company Overview: BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with more information available on their website.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Receives FDA Clearance for Clinical Study of Bria-BRES+
- FDA Clearance: BriaCell has received FDA approval to initiate a Phase 1/2a clinical study for Bria-BRES+, marking a significant advancement in personalized immunotherapy for metastatic breast cancer, which is expected to provide new treatment options for patients.
- Immune Activation Mechanism: The design of Bria-BRES+ includes additional immune-activating components aimed at enhancing clinical efficacy, potentially preventing tumor immune escape by activating both adaptive and innate immune systems, thereby increasing treatment success rates.
- Clinical Supply Preparedness: The company has prepared clinical supplies of Bria-BRES+ and plans to initiate the clinical study in the coming months, further validating its safety and efficacy in metastatic breast cancer patients and advancing the product towards market entry.
- Supporting Success Cases: In the Bria-OTS program, the first patient achieved a 100% complete resolution of lung metastasis after four doses, demonstrating the therapy's potential and providing strong support and confidence for the clinical application of Bria-BRES+.
See More
BriaCell to Present Clinical Data at 2026 ASCO Annual Meeting
- Clinical Data Presentation: BriaCell Therapeutics will showcase three clinical data posters at the 2026 ASCO Annual Meeting, focusing on survival rates and quality of life studies related to immunotherapy, which is expected to attract investor and industry attention, further enhancing the company's reputation in the biotechnology sector.
- Survival Rate Analysis: One poster will present data on survival rates at 12 and 24 months for patients with advanced metastatic breast cancer treated with Bria-IMT plus CPI, which is anticipated to provide crucial evidence for the efficacy of the treatment regimen and may facilitate the progress of subsequent clinical trials.
- Quality of Life Assessment: Another poster will explore the impact of Bria-IMT plus CPI on the quality of life and treatment tolerability for metastatic breast cancer patients, aiming to highlight the comprehensive benefits of the therapy, potentially attracting more patients to participate in clinical trials.
- Biomarker Monitoring: BriaCell will also present ongoing analyses from the randomized Bria-ABC Phase 3 trial, focusing on blood-based biomarkers as early predictors of progression-free survival, providing significant insights for future treatment strategies and potentially laying the groundwork for the company's expansion into personalized medicine.
See More
Bria-OTS+ Platform Shows Promising Advances in Cancer Immunotherapy
- Significant Immune Activation: The Bria-OTS+ platform demonstrates potent immune activation in in-vitro cancer cell models, effectively activating various immune cells including CD4⁺ and CD8⁺ T cells and NK cells, thereby enhancing tumor cell killing capacity and indicating its potential value in cancer treatment.
- Durable Anti-Tumor Activity: Bria-BRES+ and Bria-PROS+ maintain sustained cytotoxic and serial killing activity through multiple rounds of tumor cell challenges without signs of functional exhaustion, suggesting the platform may provide long-term anti-tumor effects in clinical applications.
- Broad Tumor Recognition Capability: Bria-OTS+ exhibits anti-tumor activity against multiple tumor targets, reducing the risk of immune escape, which is crucial for providing a broader immune response in cancer treatment with significant clinical implications.
- Preclinical Research Progress: BriaCell plans to enter clinical trials in 2026 for its first indications of metastatic breast cancer and prostate cancer, with future expansions to lung cancer and melanoma, highlighting its strategic positioning in the cancer immunotherapy landscape.
See More
BriaCell Presents Positive Clinical Data at AACR 2026
- Clinical Trial Results: BriaCell's Phase 3 clinical data presented at AACR 2026 indicates that heavily pretreated metastatic breast cancer patients maintained quality of life after treatment with Bria-IMT plus immune checkpoint inhibitors, demonstrating a favorable safety profile and suggesting potential for improving patient outcomes.
- Biomarker Discovery: Further analyses of Phase 2 Bria-IMT study data have identified potential prognostic biomarkers, which could provide a basis for future personalized treatment approaches, enhancing BriaCell's competitive edge in precision medicine.
- Innovative Treatment Strategies: The clinical data supports the feasibility of decentralized treatment approaches, including potential home self-administration strategies, which not only improve patient convenience but may also reduce healthcare costs and enhance overall treatment experiences.
- Future Research Directions: The company plans to continue investigating the monitoring of PD-L1 in TMFCs to better predict responses to immune checkpoint inhibitors, a strategy that could provide new insights and opportunities for BriaCell's innovative therapies in metastatic breast cancer.
See More
BriaCell to Present Four Research Abstracts at AACR Annual Meeting
- Research Presentation: BriaCell Therapeutics announced that four research abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research Annual Meeting, showcasing the latest advancements in cancer immunotherapy, which is expected to attract industry attention and enhance the company's visibility.
- Clinical Trial Progress: One of the abstracts pertains to the pivotal Phase 3 study of Bria-IMTᵀᴹ in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), indicating a significant milestone in advancing the company's clinical trial efforts, potentially paving the way for future market applications.
- Personalized Therapy Initiative: Another study supports the Bria-OTS+ᵀᴹ personalized immunotherapy program, demonstrating BriaCell's commitment to developing innovative treatment options, which may strengthen its position in the competitive biotechnology market.
- Information Release Schedule: Poster titles and presentation details will be published on March 17, 2026, at 4:30 PM ET in the online Proceedings of AACR, providing investors and researchers with an opportunity to further understand the company's research outcomes.
See More
BriaCell and BriaPro Enter sCD80 Licensing Agreement
- Transaction Overview: BriaPro has entered into a purchase agreement with BriaCell to acquire worldwide rights to develop and commercialize sCD80, with the transaction expected to close around March 12, 2026, marking a significant advancement in cancer treatment.
- Funding Support: BriaCell will provide up to $3 million to BriaPro for research and development, aimed at accelerating the development of sCD80, which is expected to significantly enhance BriaPro's R&D capabilities and market competitiveness.
- Equity Changes: As part of the transaction, BriaPro will issue 23,972,589 common shares to BriaCell, increasing BriaCell's ownership in BriaPro to approximately 78% post-transaction, thereby strengthening its control over the subsidiary.
- Immunotherapy Potential: sCD80 has shown good tolerability and anti-tumor activity in animal models, and BriaCell plans to explore its use in combination with other immunotherapies, potentially providing new treatment options for cancer patients and holding significant market potential.
See More
BriaCell Receives FDA Clearance for Clinical Study of Bria-BRES+
- FDA Clearance: BriaCell has received FDA approval to initiate a Phase 1/2a clinical study for Bria-BRES+, marking a significant advancement in personalized immunotherapy for metastatic breast cancer, which is expected to provide new treatment options for patients.
- Immune Activation Mechanism: The design of Bria-BRES+ includes additional immune-activating components aimed at enhancing clinical efficacy, potentially preventing tumor immune escape by activating both adaptive and innate immune systems, thereby increasing treatment success rates.
- Clinical Supply Preparedness: The company has prepared clinical supplies of Bria-BRES+ and plans to initiate the clinical study in the coming months, further validating its safety and efficacy in metastatic breast cancer patients and advancing the product towards market entry.
- Supporting Success Cases: In the Bria-OTS program, the first patient achieved a 100% complete resolution of lung metastasis after four doses, demonstrating the therapy's potential and providing strong support and confidence for the clinical application of Bria-BRES+.
See More
BriaCell to Present Clinical Data at 2026 ASCO Annual Meeting
- Clinical Data Presentation: BriaCell Therapeutics will showcase three clinical data posters at the 2026 ASCO Annual Meeting, focusing on survival rates and quality of life studies related to immunotherapy, which is expected to attract investor and industry attention, further enhancing the company's reputation in the biotechnology sector.
- Survival Rate Analysis: One poster will present data on survival rates at 12 and 24 months for patients with advanced metastatic breast cancer treated with Bria-IMT plus CPI, which is anticipated to provide crucial evidence for the efficacy of the treatment regimen and may facilitate the progress of subsequent clinical trials.
- Quality of Life Assessment: Another poster will explore the impact of Bria-IMT plus CPI on the quality of life and treatment tolerability for metastatic breast cancer patients, aiming to highlight the comprehensive benefits of the therapy, potentially attracting more patients to participate in clinical trials.
- Biomarker Monitoring: BriaCell will also present ongoing analyses from the randomized Bria-ABC Phase 3 trial, focusing on blood-based biomarkers as early predictors of progression-free survival, providing significant insights for future treatment strategies and potentially laying the groundwork for the company's expansion into personalized medicine.
See More
Bria-OTS+ Platform Shows Promising Advances in Cancer Immunotherapy
- Significant Immune Activation: The Bria-OTS+ platform demonstrates potent immune activation in in-vitro cancer cell models, effectively activating various immune cells including CD4⁺ and CD8⁺ T cells and NK cells, thereby enhancing tumor cell killing capacity and indicating its potential value in cancer treatment.
- Durable Anti-Tumor Activity: Bria-BRES+ and Bria-PROS+ maintain sustained cytotoxic and serial killing activity through multiple rounds of tumor cell challenges without signs of functional exhaustion, suggesting the platform may provide long-term anti-tumor effects in clinical applications.
- Broad Tumor Recognition Capability: Bria-OTS+ exhibits anti-tumor activity against multiple tumor targets, reducing the risk of immune escape, which is crucial for providing a broader immune response in cancer treatment with significant clinical implications.
- Preclinical Research Progress: BriaCell plans to enter clinical trials in 2026 for its first indications of metastatic breast cancer and prostate cancer, with future expansions to lung cancer and melanoma, highlighting its strategic positioning in the cancer immunotherapy landscape.
See More
BriaCell Presents Positive Clinical Data at AACR 2026
- Clinical Trial Results: BriaCell's Phase 3 clinical data presented at AACR 2026 indicates that heavily pretreated metastatic breast cancer patients maintained quality of life after treatment with Bria-IMT plus immune checkpoint inhibitors, demonstrating a favorable safety profile and suggesting potential for improving patient outcomes.
- Biomarker Discovery: Further analyses of Phase 2 Bria-IMT study data have identified potential prognostic biomarkers, which could provide a basis for future personalized treatment approaches, enhancing BriaCell's competitive edge in precision medicine.
- Innovative Treatment Strategies: The clinical data supports the feasibility of decentralized treatment approaches, including potential home self-administration strategies, which not only improve patient convenience but may also reduce healthcare costs and enhance overall treatment experiences.
- Future Research Directions: The company plans to continue investigating the monitoring of PD-L1 in TMFCs to better predict responses to immune checkpoint inhibitors, a strategy that could provide new insights and opportunities for BriaCell's innovative therapies in metastatic breast cancer.
See More
BriaCell to Present Four Research Abstracts at AACR Annual Meeting
- Research Presentation: BriaCell Therapeutics announced that four research abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research Annual Meeting, showcasing the latest advancements in cancer immunotherapy, which is expected to attract industry attention and enhance the company's visibility.
- Clinical Trial Progress: One of the abstracts pertains to the pivotal Phase 3 study of Bria-IMTᵀᴹ in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), indicating a significant milestone in advancing the company's clinical trial efforts, potentially paving the way for future market applications.
- Personalized Therapy Initiative: Another study supports the Bria-OTS+ᵀᴹ personalized immunotherapy program, demonstrating BriaCell's commitment to developing innovative treatment options, which may strengthen its position in the competitive biotechnology market.
- Information Release Schedule: Poster titles and presentation details will be published on March 17, 2026, at 4:30 PM ET in the online Proceedings of AACR, providing investors and researchers with an opportunity to further understand the company's research outcomes.
See More
BriaCell and BriaPro Enter sCD80 Licensing Agreement
- Transaction Overview: BriaPro has entered into a purchase agreement with BriaCell to acquire worldwide rights to develop and commercialize sCD80, with the transaction expected to close around March 12, 2026, marking a significant advancement in cancer treatment.
- Funding Support: BriaCell will provide up to $3 million to BriaPro for research and development, aimed at accelerating the development of sCD80, which is expected to significantly enhance BriaPro's R&D capabilities and market competitiveness.
- Equity Changes: As part of the transaction, BriaPro will issue 23,972,589 common shares to BriaCell, increasing BriaCell's ownership in BriaPro to approximately 78% post-transaction, thereby strengthening its control over the subsidiary.
- Immunotherapy Potential: sCD80 has shown good tolerability and anti-tumor activity in animal models, and BriaCell plans to explore its use in combination with other immunotherapies, potentially providing new treatment options for cancer patients and holding significant market potential.
See More
